Literature DB >> 25399911

Therapeutic face of RNAi: in vivo challenges.

Hojat Borna1, Saber Imani, Maryam Iman, Sadegh Azimzadeh Jamalkandi.   

Abstract

INTRODUCTION: RNA interference is a sequence-specific gene silencing phenomenon in which small interfering RNAs (siRNAs) can trigger gene transcriptional and post-transcriptional silencing. This phenomenon represents an emerging therapeutic approach for in vivo studies by efficient delivery of specific synthetic siRNAs against diseases. Therefore, simultaneous development of synthetic siRNAs along with novel delivery techniques is considered as novel and interesting therapeutic challenges. AREAS COVERED: This review provides a basic explanation to siRNA signaling pathways and their therapeutic challenges. Here, we provide a comprehensive explanation to failed and successful trials and their in vivo challenges. EXPERT OPINION: Specific, efficient and targeted delivery of siRNAs is the major concern for their in vivo administrations. Also, anatomical barriers, drug stability and availability, immunoreactivity and existence of various delivery routes, different genetic backgrounds are major clinical challenges. However, successful administration of siRNA-based drugs is expected during foreseeable features. But, their systemic applications will depend on strong targeted drug delivery strategies.

Keywords:  RNA interference; gene therapy; small interfering RNA; small interfering RNA delivery

Mesh:

Substances:

Year:  2014        PMID: 25399911     DOI: 10.1517/14712598.2015.983070

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  26 in total

1.  Stepping toward therapeutic CRISPR.

Authors:  Keith T Gagnon; David R Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

2.  Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.

Authors:  Shanthi Ganesh; Martin L Koser; Wendy A Cyr; Girish R Chopda; Junyan Tao; Xue Shui; Bo Ying; Dongyu Chen; Purva Pandya; Edmond Chipumuro; Zakir Siddiquee; Kevin Craig; Chengjung Lai; Henryk Dudek; Satdarshan P Monga; Weimin Wang; Bob D Brown; Marc T Abrams
Journal:  Mol Cancer Ther       Date:  2016-07-07       Impact factor: 6.261

3.  Delivery of Small Interfering RNA to Inhibit Vascular Endothelial Growth Factor in Zebrafish Using Natural Brain Endothelia Cell-Secreted Exosome Nanovesicles for the Treatment of Brain Cancer.

Authors:  Tianzhi Yang; Brittany Fogarty; Bret LaForge; Salma Aziz; Thuy Pham; Leanne Lai; Shuhua Bai
Journal:  AAPS J       Date:  2016-11-23       Impact factor: 4.009

4.  Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models.

Authors:  Ana Vanessa Nascimento; Florence Gattacceca; Amit Singh; Hassan Bousbaa; Domingos Ferreira; Bruno Sarmento; Mansoor M Amiji
Journal:  Nanomedicine (Lond)       Date:  2016-03-16       Impact factor: 5.307

5.  Topical Glycyrrhizin Is Therapeutic for Pseudomonas aeruginosa Keratitis.

Authors:  Sandamali A Ekanayaka; Sharon A McClellan; Ronald P Barrett; Linda D Hazlett
Journal:  J Ocul Pharmacol Ther       Date:  2017-12-13       Impact factor: 2.671

6.  Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer.

Authors:  Canan Schumann; Stephanie Chan; Oleh Khalimonchuk; Shannon Khal; Vitaliya Moskal; Vidhi Shah; Adam W G Alani; Olena Taratula; Oleh Taratula
Journal:  Mol Pharm       Date:  2016-05-26       Impact factor: 4.939

Review 7.  Emerging potential of gene silencing approaches targeting anti-chondrogenic factors for cell-based cartilage repair.

Authors:  Andrea Lolli; Letizia Penolazzi; Roberto Narcisi; Gerjo J V M van Osch; Roberta Piva
Journal:  Cell Mol Life Sci       Date:  2017-04-22       Impact factor: 9.261

Review 8.  Alternative Splicing of ALS Genes: Misregulation and Potential Therapies.

Authors:  Benedetta Perrone; Valentina La Cognata; Teresa Sprovieri; Carmine Ungaro; Francesca Luisa Conforti; Sebastiano Andò; Sebastiano Cavallaro
Journal:  Cell Mol Neurobiol       Date:  2019-08-05       Impact factor: 5.046

9.  Structure-property relationship for in vitro siRNA delivery performance of cationic 2-hydroxypropyl-β-cyclodextrin: PEG-PPG-PEG polyrotaxane vectors.

Authors:  Vivek D Badwaik; Emilio Aicart; Yawo A Mondjinou; Merrell A Johnson; Valorie D Bowman; David H Thompson
Journal:  Biomaterials       Date:  2016-01-08       Impact factor: 12.479

10.  Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.

Authors:  Burçin Tezcanlı Kaymaz; Nur Selvi Günel; Metin Ceyhan; Vildan Bozok Çetintaş; Buket Özel; Melis Kartal Yandım; Sezgi Kıpçak; Çağdaş Aktan; Aysun Adan Gökbulut; Yusuf Baran; Buket Kosova Can
Journal:  Tumour Biol       Date:  2015-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.